Do we know everything about intermediate risk pulmonary embolism? A case report at a high complexity hospital in Medellín 2024

Abstract

Venous thromboembolic diseases such as pulmonary embolism and deep vein thrombosis are the third more prevalent cause of cardiovascular syndrome. Pulmonary embolism has an incidence of 39 to 115 in 100,000 inhabitants annually and a mortality of approximately 300,000 people every year in the United states. Some risk factors of the disease are infections, trauma, lower limb fractures, venous thromboembolic disease and major surgeries. People have symptoms like dyspnea, syncope, chest pain, dizziness and abdominal pain. It is classified according to the risk of the patient into low, low-intermediate, high-intermediate and very high; the last
one saved for patients with hemodynamic instability defined by the presence of cardiac arrest, obstructive shock and persistent hypotension. Antithrombotic therapy is the best treatment option, but in very high-risk patients, thrombolytic therapy is an option too.